Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10832562 | Molecular Genetics and Metabolism | 2015 | 8 Pages |
Abstract
Coenzyme A (CoA) is a ubiquitous cofactor involved in numerous essential biochemical transformations, and along with its thioesters is a key regulator of intermediary metabolism. Pantothenate (vitamin B5) phosphorylation by pantothenate kinase (PanK) is thought to control the rate of CoA production. Pantothenate kinase associated neurodegeneration is a hereditary disease that arises from mutations that inactivate the human PANK2 gene. Aryl phosphoramidate phosphopantothenate derivatives were prepared to test the feasibility of using phosphopantothenate replacement therapy to bypass the genetic deficiency in the Pank1â/â mouse model. The efficacies of candidate compounds were first compared by measuring the ability to increase CoA levels in Pank1â/â mouse embryo fibroblasts. Administration of selected candidate compounds to Pank1â/â mice corrected their deficiency in hepatic CoA. The PanK bypass was confirmed by the incorporation of intact phosphopantothenate into CoA using triple-isotopically labeled compound. These results provide strong support for PanK as a master regulator of intracellular CoA and illustrate the feasibility of employing PanK bypass therapy to restore CoA levels in genetically deficient mice.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Stephen P. Zano, Caroline Pate, Matthew Frank, Charles O. Rock, Suzanne Jackowski,